Fluidigm Mass Cytometry Technologies, Including CyTOF, Imaging Mass Cytometry and Maxpar Direct, Utilized in More than 100 Na...
November 03 2020 - 8:30AM
Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology
tools provider with a vision to improve life through comprehensive
health insight, today announced that its mass cytometry
technologies, including CyTOF
® , Imaging Mass
Cytometry (IMC), and Maxpar
® Direct™, have been
used in 113 National Clinical Trials listed in the
clinicaltrials.gov database. This includes 94 ongoing and 19
completed clinical trials. Twenty-five trials were initiated in
2020, three of which utilize Imaging Mass Cytometry.
Fluidigm® mass cytometry technologies have been
deployed in multiple clinical trials related to the COVID-19
pandemic, including evaluation of immune response at different
stages of the disease process and assessment of response to therapy
at the cellular and molecular levels. These technologies are also
being used in clinical trials for diverse indications and
interventions in immuno-oncology, oncology, autoimmune diseases,
vaccines, infections, surgery, blood and immune disorders,
immunology, and allergy.
“The large and growing number of clinical trials
utilizing our mass cytometry technologies is evidence of our
progress in implementing our vision to improve life through
comprehensive health insight,” said Chris Linthwaite, President and
CEO of Fluidigm. “We are gratified that our technologies are
enabling cutting-edge discoveries that have the potential to
transform clinical trial design and implementation, and we believe
that ultimately they will help to advance clinical practice to
achieve improved health outcomes.
“The rapid deployment of our technologies to
support clinical research addressing the current global health
crisis demonstrates the flexibility with which those technologies
can be adapted to meet specific and urgent research objectives,
including pandemic response.”
Examples of the diverse ways in which Fluidigm mass
cytometry technologies are being incorporated into clinical trials
as of September 30, 2020:
- “Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC)”
(NCT04378777), “a prospective observational cohort surveillance
study of up to 2,000 adult participants hospitalized with known or
presumptive COVID-19,” explores how certain immunological measures
correspond to, or may even predict, the clinical severity of
disease. Ten leading U.S. medical institutions are engaged in the
study, which is sponsored by the National Institutes of Health and
uses CyTOF and the Maxpar® Direct™ Immune Profiling Assay™.
- “Collection of Immunology Specimens From Patients With Cancer
or Blood Disorders, and Healthy Volunteers” (NCT03207854), a
retrospective clinical trial designed to “identify changes in
immune system parameters in patients receiving immunotherapies and
compare” them to changes in “patients receiving conventional
chemotherapy, targeted-agent therapy, and healthy normal
volunteers.” This trial uses CyTOF.
- “Olaparib in Treating Patients with Advanced Glioma,
Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations”
(NCT03212274), a phase II trial designed to evaluate “how well
olaparib works in treating patients with glioma,
cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations
that have spread to other places in the body and usually cannot be
cured or controlled with treatment.” An exploratory objective of
this study is to determine whether co-occurring genetic alterations
are associated with levels of 2-hydroxyglutarate (a marker of
cancer progression), treatment response, and resistance to therapy.
This trial uses CyTOF and IMC.
- “Study of a New MVA Vaccine for Hepatitis C Virus”
(NCT01296451), a study designed to assess the safety and efficacy
of a new hepatitis C virus vaccine that will also evaluate cellular
immune responses following vaccine administration. This trial uses
CyTOF to perform deep profiling of cell phenotype and functional
state, all in a single tube.
- “In-depth Immunological Investigation of COVID-19 (COntAGIouS)”
(NCT04327570), an observational clinical trial designed to provide
an “in-depth characterization of the dynamic host immune response
to coronavirus SARS-CoV-2” using a transdisciplinary approach “to
identify host factors resulting in hyper-susceptibility to
SARS-CoV-2 infection, which is urgently needed for directed medical
interventions.” This trial uses CyTOF, the Maxpar Direct Immune
Profiling Assay, and the Maxpar Pathsetter™ data analysis
solution.
Commenting on the COntAGIouS trial, Professor
Frederik De Smet, PhD, of the University of Leuven, the lead
investigator for the trial, said, “At the start of the pandemic the
clinicians in our hospital who were treating COVID-19 patients
asked us to work collaboratively with them to understand the
immunological aberrations in hospitalized patients. To address this
urgent need for knowledge, my lab combined the Maxpar Direct Immune
Profiling Assay with Maxpar Pathsetter, allowing rapid data
analysis without the immediate need for bioinformaticians.
“This is important, because when we’re evaluating
up to 40 parameters at a time for each cell—which is
straightforward using CyTOF—analyzing even a few hundred thousand
cells generates enormous amounts of data. With Maxpar Pathsetter we
were able to establish a data analysis structure that rapidly
yielded results that helped inform our understanding of the immune
response to the virus and provided insights into how to potentially
improve management of infected patients. In addition, we
performed extensive bioinformatics analyses to integrate all 40
markers to a maximal extent and deep-phenotype each blood
sample.”
About
FluidigmFluidigm (Nasdaq:FLDM) focuses on the most
pressing needs in translational and clinical research, including
cancer, immunology, and immunotherapy. Using proprietary
CyTOF and microfluidics technologies, we develop, manufacture,
and market multi-omic solutions to drive meaningful insights in
health and disease, identify biomarkers to inform decisions, and
accelerate the development of more effective therapies. Our
customers are leading academic, government, pharmaceutical,
biotechnology, plant and animal research, and clinical laboratories
worldwide. Together with them, we strive to increase the quality of
life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF,
Direct, Imaging Mass Cytometry, IMC, Immune Profiling Assay,
Maxpar, and Pathsetter are trademarks and/or registered trademarks
of Fluidigm Corporation in the United
States and/or other countries. All other trademarks are the
sole property of their respective owners. Fluidigm products are
provided for Research Use Only. Not for use in diagnostic
procedures.
Forward-Looking Statements for
Fluidigm This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including, among others, statements regarding
the impact of Fluidigm mass cytometry technologies on clinical
trials and health care. Forward-looking statements are subject to
numerous risks and uncertainties that could cause actual results to
differ materially from currently anticipated results, including but
not limited to risks relating to challenges inherent in developing,
manufacturing, launching, marketing, and selling new products;
risks relating to company research and development and distribution
plans and capabilities; reductions in research and development
spending or changes in budget priorities by customers; potential
product performance and quality issues; intellectual property
risks; and competition. Information on these and additional risks
and uncertainties and other information
affecting Fluidigm business and operating results is
contained in Fluidigm’s Annual Report on Form 10-K for the year
ended December 31, 2019, and in its other filings with
the Securities and Exchange Commission. These forward-looking
statements speak only as of the date
hereof. Fluidigm disclaims any obligation to update these
forward-looking statements except as may be required by law.
Available InformationWe use our
website (fluidigm.com), investor site (investors.fluidigm.com),
corporate Twitter account (@fluidigm), Facebook page
(facebook.com/Fluidigm), and LinkedIn page
(linkedin.com/company/fluidigm-corporation) as channels of
distribution of information about our products, our planned
financial and other announcements, our attendance at upcoming
investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and
webcasts.
Fluidigm
Media:Mark SpearmanSenior
Director, Corporate Communications650 243
6621mark.spearman@fluidigm.com
Investors:Agnes LeeVice President,
Investor Relations650 416 7423agnes.lee@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Apr 2023 to Apr 2024